ArticleCancer biology & medicine2018

Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway.

Yehui Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.